HCA Healthcare UK is heading to Arab Health 2020, with members of its newly formed International Services Group, dedicated to developing HCA UK’s already strong presence in the international market.

Joining forces with the Harley Street Medical Area, Nikesh Davda, Vice President of HCA UK’s International Services Group and team will showcase the personalised, expert and high-quality complex care available at HCA UK Hospitals, several of which are in and around the world-renowned Harley Street area.

Across HCA UK’s network of six flagship hospitals (The Harley Street Clinic, The Portland Hospital, The Princess Grace Hospital, The Wellington Hospital, London Bridge Hospital and The Lister Hospital) and two joint ventures with NHS Trusts; University College London Hospitals and The Christie, HCA UK provide the depth and breadth of care to international patients not available elsewhere in the UK private sector.

Working in partnership with over 2000 consultants with backgrounds in NHS teaching hospitals and research, HCA UK offers specialist and complex care including; stem cell transplants, cancer care including immunotherapy and CAR-T cell therapy, trans-oral robotic surgery for hard-to-reach head and neck tumours, coronary care and the UK’s only wholly private hospital for women and children.

With unrivalled longevity in the UK healthcare market and over 20 years’ experience of caring for patients from across the globe, HCA UK also offer tailored services for international patients including a VIP Personal Medical Concierge service, on-site interpreters and dedicated assistance with the admissions process.

Nikesh Davda, Vice President of HCA UK’s International Service Group said;

“We are proud that every year thousands of patients from across the globe choose HCA Healthcare UK hospitals. Our experience in delivering care across the depth and breadth of specialisms for adults and children has helped establish our reputation as a preferred provider of highly quality complex care.

“The International Services Group is committed to maintaining and building this reputation, providing care and the improvement of human life to our international patients and their families through seamless patient pathways from in-country, to our HCA Facilities and back home again`

“Working with the Harley Street Medical Area at Arab Health is great opportunity for us to showcase our offer, and it’s a privilege to be representing such an iconic location synonymous with pioneering medicine.”

HCA UK is joining the HSMA delegation at Arab Health 2020 – as part of the 17 world-leading clinics and hospital groups showcasing London’s medical excellence at the largest healthcare trade exhibition in the Middle East.

The Arab Health Exhibition and Congress is the largest healthcare event in the Middle East. The event takes place 27 January – 30 January 2020 at the Dubai World Trade Centre, Dubai, UAE.

More information about HCA Healthcare UK

HCA Healthcare UK includes London Bridge Hospital, The Portland Hospital, The Harley Street Clinic, The Lister Hospital, The Princess Grace Hospital, The Wellington Hospital, Roodlane Medical Ltd, and Blossoms Healthcare. HCA UK also partners with leading NHS Trusts to provide care at The Christie Private Care, HCA UK at University College Hospital and Private Care at Guy’s.

HCA UK has also started construction on a new £100m hospital in Birmingham in partnership with University Hospitals Birmingham.

https://www.hcahealthcare.co.uk/

Nikesh Davda, Vice President of HCA Healthcare UK’s International Services Group, was formerly Chief Financial Officer of HCA UK’s The Wellington Hospital. The newly formed International Services Group, has been created to bring together all aspects of the patient pathway and management of our provision of care to deliver the highest quality service to our international patients.

The International Services Group is committed to be the preferred provider of care to international patients, delivering the improvement of human life through a pathway from in-country through to HCA UK and back to in-country.

More information about Harley Street Medical Area

The Howard de Walden Estate is the guardian of the Harley Street Medical Area and has been supporting and nurturing medical excellence in this historic part of London for 200 years. The Harley Street Medical Area is a collective of hospitals, clinics and specialists who deliver outstanding patient care through pioneering treatments and cutting-edge technologies. With over 5000 medical specialists and over 250 clinics working within 92 acres of Marylebone, central London, it brings together a community of medical professionals, providing access to the best medical treatments and services in the world.

Cleveland Clinic London is attending Arab Health 2020 to provide an update on their state-of-the-art facilities opening soon in London – its first in Europe.

Tommaso Falcone, MD, Chief of Staff, Chief Academic Officer and Medical Director at Cleveland Clinic London, will talk about delivering one of the most technologically advanced private hospitals in the UK, and a new model of care for London.

Ranked in the top two hospitals in the world*, Cleveland Clinic will open its first medical outpatient building at 24 Portland Place, near Harley Street, which is expected to begin seeing patients in November 2020 for outpatient appointments and diagnostics, and general practice appointments.

It marks a major milestone in Cleveland Clinic London’s development and further demonstrates its commitment to London and the UK healthcare market in advance of Cleveland Clinic London Hospital opening in Spring 2021.

The new hospital at 33 Grosvenor Place – an eight-story, 324,000-square-foot building – is currently under construction. The hospital will offer an exceptional quality of care through its doctor-led model, which is unique in London private healthcare. It will also provide new jobs and employment opportunities for a variety of clinical and non-clinical employees.

Tommaso Falcone said: “Cleveland Clinic London will be one of the most technologically advanced hospitals in the UK. We will combine the best of Cleveland Clinic in the US with London’s top-quality talent and research, to innovate and provide a doctor-led model of care that will offer exceptional clinical quality and patient safety.”

Cleveland Clinic London will have 185 inpatient beds; eight operating rooms; a full imaging suite; endoscopy and catheterization labs; day case rooms for surgery; and a full neurological suite with rehabilitation. The facility will offer specialty services focusing on general surgery, cardiology, orthopaedics and neurology.

Cleveland Clinic is also prioritising the reduction of the building’s environmental impact once operational. The building will produce its own heat and power, significantly minimising carbon emissions from air and water heating. The cutting-edge of hospital design will create an environment that reflects the needs of patients and the future of healthcare in the UK, while ensuring that the building has minimal environmental impact.

The hospital will be Cleveland Clinic’s first facility in Europe, adding another international location to a health system that includes a 165-acre main campus near downtown Cleveland, 11 regional hospitals throughout Northeast Ohio, multiple facilities in Florida, a facility in Las Vegas, Nev., and hospitals in Toronto, Canada; and Abu Dhabi, UAE.

More info about Harley Street Medical Area
The Howard de Walden Estate is the guardian of the Harley Street Medical Area and has been supporting and nurturing medical excellence in this historic part of London for 200 years. The Harley Street Medical Area is a collective of hospitals, clinics and specialists who deliver outstanding patient care through pioneering treatments and cutting-edge technologies. With over 5000 medical specialists and over 250 clinics working within 92 acres of Marylebone, central London, the Harley Street Medical Area brings together a community of medical professionals, providing access to the best medical treatments and services in the world.

About Cleveland Clinic
Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S. News & World Report consistently names Cleveland Clinic as one of the nation’s best hospitals in its annual “America’s Best Hospitals” survey. Among Cleveland Clinic’s 66,000 employees are more than 4,200 salaried physicians and researchers and 16,600 nurses, representing 140 medical specialties and subspecialties. Cleveland Clinic’s health system includes a 165-acre main campus near downtown Cleveland, 11 regional hospitals in northeast Ohio, more than 180 northern Ohio outpatient locations – including 18 full-service family health centers and three health and wellness centers – and locations in southeast Florida; Las Vegas, Nev.; Toronto, Canada; Abu Dhabi, UAE; and London, England. In 2018, there were 7.9 million total outpatient visits, 238,000 hospital admissions and observations, and 220,000 surgical cases throughout Cleveland Clinic’s health system. Patients came for treatment from every state and 185 countries. Visit us at clevelandclinic.org. Follow us at twitter.com/CCforMedia and twitter.com/ClevelandClinic. News and resources available at newsroom.clevelandclinic.org.

Ra Medical Systems, Inc , a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces approval from the U.S. FDA that the Company has provided sufficient data to support initiating an investigational device exemption (IDE) to evaluate the safety and effectiveness of the DABRA excimer laser system for use as an atherectomy device for the treatment of peripheral vascular stenoses. In May 2017, DABRA received FDA 510(k) clearance for use in ablating a channel in occlusive peripheral vascular disease (PAD).

“We are delighted the FDA has granted this IDE allowing us to pursue an atherectomy indication for DABRA and anticipate enrolling the first patient into the trial in the next few months,” said Andrew Jackson, Ra Medical Systems CFO and Interim CEO. “We believe DABRA produces minimal vascular trauma due to its unique use of photochemical ablation that dissolves plaque into its molecular components, which may make DABRA a preferred treatment. Atherectomy with mechanical devices can cause trauma to vessel walls, often resulting in restenosis or a return of the blockage months following the procedure.”

The multicenter, open-label trial will enroll up to 100 patients with symptoms of PAD (Rutherford Class 2-4). Outcome measures include safety, acute technical success and clinical success. The trial’s primary efficacy endpoint is the mean reduction in percent diameter stenosis in each patient’s primary lesion as measured by angiography immediately following treatment with DABRA, before any adjunctive treatment. Major adverse events at 30 days and incidence of primary target lesion revascularization (TLR) at six months will be the safety and clinical success endpoints.

About DABRA

DABRA is Ra Medical’s minimally invasive excimer laser system used by physicians as a tool in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease, a form of PAD, both above and below the knee. DABRA reduces all four plaque types into their fundamental chemistry, such as proteins, lipids and other chemical compounds, eliminating blockages by essentially dissolving them without generating potentially harmful particulates. DABRA employs photochemical ablation, or the removal of arterial tissue by using photons to clear blockages by breaking the bonds of the obstructing plaque. Unlike many treatments for PAD that may damage the arterial wall, DABRA quickly and photochemically dissolves plaque with minimal vascular trauma.

About Ra Medical Systems

Ra Medical Systems commercializes excimer lasers and catheters for the treatment of vascular and dermatological diseases. In May 2017, the DABRA excimer laser system received FDA 510(k) clearance in the U.S. for crossing chronic total occlusions, or CTOs, in patients with symptomatic infrainguinal lower extremity vascular disease with an intended use for ablating a channel in occlusive peripheral vascular disease. Pharos excimer laser system is FDA-cleared and is used as a tool in the treatment of psoriasis, vitiligo, atopic dermatitis and leukoderma. DABRA and Pharos are both based on Ra Medical’s core excimer laser technology platform and deploy similar mechanisms of action. Ra Medical manufactures DABRA and Pharos excimer lasers and catheters in a 32,000-square-foot facility located in Carlsbad, Calif. The vertically integrated facility is ISO 13485 certified and is licensed by the State of California to manufacture sterile, single-use catheters in controlled environments.

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, announced its commercial launch of the t:slim X2™ insulin pump with Control-IQ  technology, an advanced hybrid-closed loop feature designed to help increase time in range (70-180 mg/dL)1. It is the first and only system cleared to deliver automatic correction boluses in addition to adjusting insulin to help prevent high and low blood sugar.

The system integrates with Dexcom G6 continuous glucose monitoring (CGM), which requires no fingersticks for calibration or diabetes treatment decisions.2,3,4 The Company will soon begin sending emails with update instructions to all in-warranty t:slim X2 users in the United States, who have the option to add the new feature free of charge via remote software update. t:slim X2 pumps pre-loaded with Control-IQ technology are now shipping to new customers.

The t:slim X2 insulin pump with Control-IQ technology uses CGM values, in conjunction with other variables such as insulin on board, to predict sensor glucose levels 30 minutes ahead and adjust insulin delivery accordingly. If glucose values are predicted to drop below 112.5 mg/dL, basal insulin delivery is reduced, and when predicted to be below 70 mg/dL, basal insulin delivery is stopped. If glucose values are predicted to be above 160 mg/dL in the next 30 minutes, basal insulin will be increased. If glucose values are predicted to be above 180 mg/dL, Control-IQ technology calculates a correction bolus with a target of 110 mg/dL, and delivers 60 percent of that value up to once an hour as needed. Control-IQ technology also offers optional settings for sleep and exercise that will change treatment values to better match the different physiologic needs during these activities.

“Control-IQ technology has been described by study participants and investigators as ‘life-changing,’ ‘easy to use,’ and ‘a new standard of care in insulin therapy management,’ which is incredible feedback as we commence this commercial launch and begin bringing its benefits to more people with diabetes,” said John Sheridan, President and Chief Executive Officer. “We began processing orders earlier this month and are excited about the opportunity this launch presents for 2020. As these new customers move through the insurance verification process it will provide us with valuable trend information that will be used in setting our financial guidance for the year.”

Update Instructions for Current t:slim X2 Pump Users

No action is required at this time. Individual emails are being sent to all in-warranty t:slim X2 pump users in the United States with information on how to start the update process. Emails are being sent out in batches, with all users anticipated to have received the information by the end of January. The Control-IQ technology update will require a new prescription and completion of online training, all of which will be coordinated through a simple-to-use online portal. Internet and computer access are required for pump updates. Control-IQ technology is only compatible with the Dexcom G6 CGM System. t:slim X2 insulin pumps updated to Control-IQ technology cannot revert to previous software versions following this software update. More information about the update process and system requirements is available at www.tandemdiabetes.com/X2update.

Free Demo App – Control-IQ Technology

Tandem’s free t:simulator™ app lets people experience the touchscreen interface of the t:slim X2 pump with Control-IQ technology directly on a mobile device. For more information and to download the app, visit http://www.tandemdiabetes.com/tsimulator.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. The t:slim X2 pump is capable of remote feature updates using a personal computer. Tandem is based in San Diego, California.

Important Safety Information for the t:slim X2 Insulin Pump with Control-IQ Technology

Caution: Federal (USA) law restricts the t:slim X2 insulin pump and Control-IQ technology to sale by or on the order of a physician.

Indications for Use:

t:slim X2 insulin pump

The t:slim X2 insulin pump with interoperable technology is an alternate controller enabled (ACE) pump that is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in individuals 6 years of age and greater. The pump is intended for single patient, home use and requires a prescription. The pump is indicated for use with NovoLog or Humalog U-100 insulin.

Control-IQ technology

Control-IQ technology is intended for use with a compatible integrated continuous glucose monitor (iCGM, sold separately) and ACE pump to automatically increase, decrease, and suspend delivery of basal insulin based on CGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ technology is intended for the management of Type 1 diabetes mellitus in persons 14 years of age and greater. Control-IQ technology is intended for single patient use. Control-IQ technology is indicated for use with NovoLog or Humalog U-100 insulin.

Contraindications and Warnings:

BOXED WARNING: Control-IQ technology should not be used by anyone under the age of six years old. It should also not be used in patients who require less than 10 units of insulin per day or who weigh less than 55 pounds.

Control-IQ technology is not indicated for use in pregnant women, persons on dialysis, or critically ill patients.

Users of the t:slim X2 pump and Control-IQ technology must:

• be able and willing to use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use;
• test blood glucose levels as recommended by their healthcare provider;
• demonstrate adequate carb-counting skills;
• maintain sufficient diabetes self-care skills;
• see healthcare provider(s) regularly; and
• have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders;

The t:slim X2 pump, transmitter, and sensor must be removed before MRI, CT, or diathermy treatment. For additional important safety information, visit tandemdiabetes.com/safetyinfo.

Tandem Diabetes Care and Basal-IQ are registered trademarks, and t:slim X2, Control-IQ and t:simulator are trademarks of Tandem Diabetes Care, Inc.Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. All other third-party marks are the property of their respective owners.

KT Corporation Korea’s largest telecommunications company, and the Samsung Medical Center (SMC) announced last week that they have jointly developed an innovative, 5G-powered medical service as an initial step to establishing a 5G smart hospital.

For the pilot project, KT built an enterprise-dedicated 5G network at the SMC, __create__d service environments in operating and proton therapy rooms, and conducted a test operation. Based on the project’s outcome, the two parties plan to continue to develop smart patient care and 5G-powered innovative medical practices and improve hospital operational efficiency.

“KT, in partnership with the Samsung Medical Center, is pioneering innovative medical services for the new 5G era,” said Park In-Young, Vice President of KT’s ICT Convergence Business Department. “We will continue to further refine 5G-powered medical technology by applying VR and AR technologies for real-time education.”

The two partners have been applying 5G on site to __create__ better medical services since they signed a memorandum of understanding in September 2019. These services include digital diagnostic pathology, access to proton therapy information, teaching surgery, an artificial intelligence-enabled care for in-patients, and an autonomous robot for an operating room.

Access to Digital Data and Video Footage

The 5G-powered digital pathological analysis conducted by SMC is a world-first example of innovation using 5G technology for on-site medical procedures.

In diagnostic pathology practiced up to now at one of Korea’s biggest hospitals, tissues taken from the patient during surgery were treated for analysis and sent to pathologists in an adjacent room. This required up to 20 minutes of walking back and forth, making it difficult for pathologists to conduct on-site group analyses.

Speedy and uninterrupted access to pathological data obtained during surgery, which is critical in determining the conditions of patients, is provided by a 5G network with ultra-high speed and ultra-low latency. The network allows the Pathology Department to gain access to materials, each containing about 4GB of data, ensuring better medical services.

The network also provides speedy access to CT and MRI data on proton therapy. The procedure required the pathologists to walk about a kilometer to the proton therapy center to download the files. Now, the 5G network enables them to access the files from anywhere within the medical center.

Surgery Education Away from the Operating Room

Operating rooms are too crowded with surgeons, nurses and medical equipment for medical students to observe closely. Resolving the hurdle to effective teaching, KT has developed a 5G-assisted education program in cooperation with the Samsung Medical Center.

The program enables surgeons in operating room to teach a large group of medical trainees in a separate lecture room, using sync cams on the 5G network. It provides voice and high-quality video footage from the perspective of the surgeons in real time.

Robots for Operating Room Assistance; AI for In-Patient Care

A delivery robot developed for operating rooms can remove contaminated materials and other medical waste for disposal. The autonomous robot can also bring in surgery supplies.

Robots for operating room assistance will reduce secondary and tertiary infection which occurs through contact with medical waste and save human resource costs in waste disposal. Moreover, 5G-enabled massive connectivity minimizes disruption and latency in data exchange with robots and terminals.

Smart Care Giver is an innovative AI-assisted system of in-patient care. It provides AI services on KT’s GiGAGenie engine, enabling patients to control their hospital room with a voice command, and with their permission checking their medical condition. Hence the medical staff can respond more efficiently to patient emergencies.

5G-Powered Smart Hospital

Collaboration between KT and the Samsung Medical Center will continue beyond the development of innovative medical service during this year.

“Based on the verified new services, we will continue our collaboration with KT to promote convenience for all of our customers, including patients, medical staff and visitors,” said Professor Park Seung-Woo, who is in charge of the smart hospital project at the SMC.

ABOUT KT CORPORATION (KRX: 030200; NYSE: KT)
KT Corporation, Korea’s largest telecommunications service provider, is leading the era of innovations in the world’s most connected country. The company is leading the fourth industrial revolution with high speed wire/wireless network and new ICT technology. KT launched the world’s first nationwide commercial 5G network on April 3, 2019, after successfully showcasing the world’s first trial 5G services at the PyeongChang Winter Olympic Games in February 2018. This is another milestone in KT’s continuous efforts to deliver essential products and services as it aspires to be the number one ICT Company and People’s Company.